Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Androgen receptor-dependent DRAM1 activation drives autophagic resistance to BRAF inhibitors in BRAFV600-mutant melanoma.

Cell death & disease - 16 Mar 2026

Zhi Ding, Wu Baojin, Yang Junyi, Wang Daohe, Qiao Jing, Guo Fanli

Abstract excerpt

BRAFV600-mutant melanoma relies on hyperactivation of the MAPK/ERK pathway for tumorigenesis, with BRAF/MEK inhibitors (BRAFi/MEKi) improving patient outcomes. However, therapeutic resistance frequently emerges, and male patients show poorer responses and outcomes, partially linked to androgen receptor (AR) overexpression. Here, we uncover a mechanistic link between AR signaling and autophagic resistance in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autophagy
Share to Cell Line, Tumor
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Membrane Proteins

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Receptors, Androgen

Source

Open in PubMed Open full text

Identifiers

PMID: 41839860
DOI: 10.1038/s41419-026-08547-x
PMCID: PMC13004951

Genes

AR
BRAF
DRAM1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Androgen receptor-dependent DRAM1 activation drives autophagic resistance to BRAF inhibitors in BRAFV600-mutant melanoma.PMID 41839860Read ↗

Androgen receptor activity promotes resistance to BRAF-targeted melanoma therapySemantic proximity Read ↗

Androgen Receptor is a Determinant of Melanoma targeted drug resistanceSemantic proximity Read ↗

Autophagy- An emerging target for melanoma therapySemantic proximity Read ↗

ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant MelanomaSemantic proximity Read ↗

The Role of Autophagy in the Resistance to BRAF Inhibition in BRAF-Mutated MelanomaSemantic proximity Read ↗

Overcoming Resistance to Therapies Targeting the MAPK Pathway in BRAF-Mutated TumoursSemantic proximity Read ↗

Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studiesSemantic proximity Read ↗

The Cytoprotective Role of Autophagy in Response to BRAF-Targeted Therapies.Semantic proximity Read ↗

Transcriptional regulation of autophagy-lysosomal function in BRAF-driven melanoma progression and chemoresistanceSemantic proximity Read ↗

The AhR-SRC axis as a therapeutic vulnerability in BRAFi-resistant melanoma.Semantic proximity Read ↗

Loss of HAT1 expression confers BRAFV600E inhibitor resistance to melanoma cells by activating MAPK signaling via IGF1RSemantic proximity Read ↗

Targeting Autophagy in BRAF-Mutant Tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.